Gala­pa­gos beefs up its fi­bro­sis pipeline, las­so­ing 4 more pro­grams and tak­ing a stake in small Cana­di­an part­ner

With big mon­ey pacts with Gilead and Ab­b­Vie un­der its belt, Gala­pa­gos has be­come a hefty part­ner to small­er biotech play­ers in its own right.

The Bel­gian biotech has ex­pand­ed a col­lab­o­ra­tion with Fi­bro­cor Ther­a­peu­tics — grab­bing ex­clu­sive op­tions to four more fi­bro­sis pro­grams and tak­ing an eq­ui­ty stake in the com­pa­ny. Once Fi­bro­cor com­pletes the re­search work up to lead op­ti­miza­tion, Gala­pa­gos may take over de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.